Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …
vaccination was implemented. We did a systematic review and meta-analysis of the …
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia
FX Bosch, AN Burchell, M Schiffman, AR Giuliano… - Vaccine, 2008 - Elsevier
Worldwide human papillomavirus (HPV) prevalence in women with normal cytology at any
given point in time is approximately 10% indicating that HPV is one of the most common …
given point in time is approximately 10% indicating that HPV is one of the most common …
[HTML][HTML] A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
[HTML][HTML] Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
Background Endometriosis is a risk factor for epithelial ovarian cancer; however, whether
this risk extends to all invasive histological subtypes or borderline tumours is not clear. We …
this risk extends to all invasive histological subtypes or borderline tumours is not clear. We …
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
Context Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry
deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2 …
deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2 …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of
multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed∼ 480 …
multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed∼ 480 …
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence
SK Kjær, K Frederiksen, C Munk… - Journal of the National …, 2010 - academic.oup.com
Background Infection with high-risk human papillomavirus (HPV) is the main cause of high-
grade cervical intraepithelial neoplasia (CIN) and cancer. It has been suggested that …
grade cervical intraepithelial neoplasia (CIN) and cancer. It has been suggested that …
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
N Muñoz, SK Kjaer, K Sigurdsson… - Journal of the …, 2010 - academic.oup.com
Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …